JP2024513644A - Ｖｅｇｆａ結合分子 - Google Patents

Ｖｅｇｆａ結合分子 Download PDF

Info

Publication number
JP2024513644A
JP2024513644A JP2023550275A JP2023550275A JP2024513644A JP 2024513644 A JP2024513644 A JP 2024513644A JP 2023550275 A JP2023550275 A JP 2023550275A JP 2023550275 A JP2023550275 A JP 2023550275A JP 2024513644 A JP2024513644 A JP 2024513644A
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
antigen
vegfa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023550275A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024513644A5 (https=
Inventor
アシアル，イグナシオ
Original Assignee
ドットバイオ プライベート リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ドットバイオ プライベート リミテッド filed Critical ドットバイオ プライベート リミテッド
Publication of JP2024513644A publication Critical patent/JP2024513644A/ja
Publication of JP2024513644A5 publication Critical patent/JP2024513644A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/515—Angiogenesic factors; Angiogenin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023550275A 2021-02-19 2022-02-18 Ｖｅｇｆａ結合分子 Pending JP2024513644A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG10202101681W 2021-02-19
SG10202101681W 2021-02-19
PCT/EP2022/054137 WO2022175481A1 (en) 2021-02-19 2022-02-18 Vegfa-binding molecules

Publications (2)

Publication Number Publication Date
JP2024513644A true JP2024513644A (ja) 2024-03-27
JP2024513644A5 JP2024513644A5 (https=) 2025-02-26

Family

ID=80685523

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023550275A Pending JP2024513644A (ja) 2021-02-19 2022-02-18 Ｖｅｇｆａ結合分子
JP2023550552A Active JP7827737B2 (ja) 2021-02-19 2022-02-18 Ｖｅｇｆａ結合分子

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023550552A Active JP7827737B2 (ja) 2021-02-19 2022-02-18 Ｖｅｇｆａ結合分子

Country Status (9)

Country Link
US (2) US20240228602A9 (https=)
EP (2) EP4294839A1 (https=)
JP (2) JP2024513644A (https=)
KR (2) KR20230165902A (https=)
CN (2) CN117242092A (https=)
AR (1) AR124917A1 (https=)
AU (2) AU2022223337A1 (https=)
CA (2) CA3208389A1 (https=)
WO (2) WO2022175481A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119790077A (zh) * 2022-09-14 2025-04-08 寻济生物科技（北京）有限公司 一种抗vegfa融合蛋白及其制备方法和应用
AU2023340044A1 (en) * 2022-09-14 2025-04-03 Quaerite Biopharm Research (Beijing) Co., Ltd. Anti-vegfa antibody or antigen-binding fragment thereof and use thereof
CN119039450A (zh) * 2023-05-22 2024-11-29 上海君实生物医药科技股份有限公司 抗pd-1-抗vegf的双特异性抗体、其药物组合物及其用途

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010528647A (ja) * 2007-06-06 2010-08-26 ドマンティス リミテッド ポリペプチド、抗体可変ドメインおよびアンタゴニスト
JP2010529853A (ja) * 2007-06-13 2010-09-02 コリア リサーチ インスティチュート オブ バイオサイエンス アンド バイオテクノロジー 血管内皮成長因子（ｖｅｇｆ）受容体を中和するヒトモノクローナル抗体及びその用途
JP2013541939A (ja) * 2010-09-03 2013-11-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｖｅｇｆ結合分子
JP2014515602A (ja) * 2011-04-01 2014-07-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ＶＥＧＦ及びＡｎｇ２と結合する二重特異性結合分子
JP2014523746A (ja) * 2011-07-27 2014-09-18 グラクソ グループ リミテッド Ｆｃドメインと融合した抗ｖｅｇｆ単一可変ドメイン
JP2018500879A (ja) * 2014-11-05 2018-01-18 ナンヤン テクノロジカル ユニヴァーシティー 安定化かつ自律性抗体ｖｈドメイン
US20180169228A1 (en) * 2015-01-06 2018-06-21 Zhuhai Essex Bio-Pharmaceutical Co., Ltd. Anti-vegf antibody
CN110452297A (zh) * 2019-09-03 2019-11-15 上海洛启生物医药技术有限公司 抗vegf单域抗体及其应用
JP2020504623A (ja) * 2017-01-05 2020-02-13 へリックス バイオファーマ コープ． 癌を治療するためのｖｅｇｆｒ−２ ｃａｒ免疫細胞

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010528647A (ja) * 2007-06-06 2010-08-26 ドマンティス リミテッド ポリペプチド、抗体可変ドメインおよびアンタゴニスト
JP2010529853A (ja) * 2007-06-13 2010-09-02 コリア リサーチ インスティチュート オブ バイオサイエンス アンド バイオテクノロジー 血管内皮成長因子（ｖｅｇｆ）受容体を中和するヒトモノクローナル抗体及びその用途
JP2013541939A (ja) * 2010-09-03 2013-11-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｖｅｇｆ結合分子
JP2014515602A (ja) * 2011-04-01 2014-07-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ＶＥＧＦ及びＡｎｇ２と結合する二重特異性結合分子
JP2014523746A (ja) * 2011-07-27 2014-09-18 グラクソ グループ リミテッド Ｆｃドメインと融合した抗ｖｅｇｆ単一可変ドメイン
JP2018500879A (ja) * 2014-11-05 2018-01-18 ナンヤン テクノロジカル ユニヴァーシティー 安定化かつ自律性抗体ｖｈドメイン
US20180169228A1 (en) * 2015-01-06 2018-06-21 Zhuhai Essex Bio-Pharmaceutical Co., Ltd. Anti-vegf antibody
JP2020504623A (ja) * 2017-01-05 2020-02-13 へリックス バイオファーマ コープ． 癌を治療するためのｖｅｇｆｒ−２ ｃａｒ免疫細胞
CN110452297A (zh) * 2019-09-03 2019-11-15 上海洛启生物医药技术有限公司 抗vegf单域抗体及其应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FATEMEH KAZEMI-LOMEDASHT, ET AL.: "Inhibition of angiogenesis in human endothelial cell using VEGF specific nanobody", MOLECULAR IMMUNOLOGY, vol. 65, JPN7026000206, 2015, pages 58 - 67, ISSN: 0005778318 *
WALEAD EBRAHIMIZADEH, ET AL.: "Production of Novel VHH Nanobody Inhibiting Angiogenesis by Targeting Binding Site of VEGF", APPL BIOCHEM BIOTECHNOL, vol. 176, JPN7026000204, 9 June 2015 (2015-06-09), pages 1985 - 1995, ISSN: 0005778320 *
ZAHRA FARAJPOUR, ET AL.: "A nanobody directed to a functional epitope on VEGF, as a novel strategy for cancer treatment", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 446, JPN7026000205, 22 February 2014 (2014-02-22), pages 132 - 136, ISSN: 0005778319 *

Also Published As

Publication number Publication date
WO2022175474A1 (en) 2022-08-25
CN117242092A (zh) 2023-12-15
KR20230165902A (ko) 2023-12-05
AR124917A1 (es) 2023-05-17
AU2022223337A1 (en) 2023-09-21
CN117279941A (zh) 2023-12-22
US20240228602A9 (en) 2024-07-11
AU2022222311A1 (en) 2023-09-21
EP4294838A1 (en) 2023-12-27
JP2024512260A (ja) 2024-03-19
KR20230165901A (ko) 2023-12-05
JP7827737B2 (ja) 2026-03-10
US20240228601A9 (en) 2024-07-11
US20240132580A1 (en) 2024-04-25
WO2022175481A1 (en) 2022-08-25
US20240132579A1 (en) 2024-04-25
EP4294839A1 (en) 2023-12-27
CA3208389A1 (en) 2022-08-25
CA3208368A1 (en) 2022-08-25

Similar Documents

Publication Publication Date Title
TWI883044B (zh) 使用her3抗原結合分子的癌症之治療及預防
JP7825000B2 (ja) Ｈｅｒ３抗原結合性分子
JP7295146B2 (ja) 抗－ｒｏｒ１抗体およびその用途
JP7827737B2 (ja) Ｖｅｇｆａ結合分子

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240712

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250217

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260421